companies / axonistx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-18 json
| total_raised | 150,000,000150.0M | ○ |
|---|---|---|
| founded | 2020 | |
| hq | Boston, MA | |
| industry | unknown | |
| stage | series-a |
Axonis Therapeutics develops drugs targeting KCC2, a brain protein central to neural inhibition, with lead candidate AXN-027 for epilepsy and chronic pain. It aims to treat patients with epilepsy, pain, and other central nervous system disorders. Its proprietary KCC2 discovery engine is built on research spun out of Boston Children's Hospital, Harvard, and Laval University.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-10-01 | series-a | 115,000,000115.0M | null | ○ |
| fact | status | src |
|---|---|---|
| Series A, $115.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |